BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,595,287 | +3.1% | 225,323 | +2.5% | 0.02% | +11.1% |
| Q2 2023 | $1,546,927 | -15.5% | 219,734 | +0.1% | 0.02% | -18.2% |
| Q1 2023 | $1,830,722 | -57.6% | 219,511 | -41.6% | 0.02% | -59.3% |
| Q4 2022 | $4,314,505 | +65.6% | 375,828 | +81.8% | 0.05% | +54.3% |
| Q3 2022 | $2,605,000 | +19.1% | 206,738 | 0.0% | 0.04% | +25.0% |
| Q2 2022 | $2,187,000 | -36.1% | 206,738 | -1.8% | 0.03% | -22.2% |
| Q1 2022 | $3,424,000 | +16.7% | 210,565 | -0.6% | 0.04% | +20.0% |
| Q4 2021 | $2,934,000 | +11.3% | 211,858 | +15.5% | 0.03% | +15.4% |
| Q3 2021 | $2,636,000 | – | 183,433 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |